Peak Financial Advisors LLC Takes $489,000 Position in Boston Scientific Corporation $BSX

Key Points

• Peak Financial Advisors LLC purchased a new stake in Boston Scientific Corporation, acquiring 4,551 shares valued at approximately $489,000 during the second quarter.
• Boston Scientific recently reported earnings of $0.75 per share, beating analyst expectations, with a revenue of $5.06 billion for the quarter—22.8% higher than the same period last year.
• Institutional investors own 89.07% of Boston Scientific's stock, with several hedge funds increasing their stakes in the company recently.

Peak Financial Advisors LLC acquired a new stake in Boston Scientific Corporation (NYSE:BSX - Free Report) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 4,551 shares of the medical equipment provider's stock, valued at approximately $489,000.

Several other hedge funds and other institutional investors have also made changes to their positions in BSX. Brighton Jones LLC grew its stake in shares of Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock valued at $2,445,000 after buying an additional 226 shares in the last quarter. Bank Pictet & Cie Europe AG grew its stake in shares of Boston Scientific by 40.8% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock valued at $6,529,000 after buying an additional 21,173 shares in the last quarter. Highview Capital Management LLC DE boosted its position in Boston Scientific by 6.2% during the fourth quarter. Highview Capital Management LLC DE now owns 24,507 shares of the medical equipment provider's stock worth $2,189,000 after purchasing an additional 1,439 shares during the period. Gotham Asset Management LLC boosted its position in Boston Scientific by 43.7% during the fourth quarter. Gotham Asset Management LLC now owns 11,430 shares of the medical equipment provider's stock worth $1,021,000 after purchasing an additional 3,475 shares during the period. Finally, ProShare Advisors LLC boosted its position in Boston Scientific by 12.0% during the fourth quarter. ProShare Advisors LLC now owns 224,880 shares of the medical equipment provider's stock worth $20,086,000 after purchasing an additional 24,022 shares during the period. 89.07% of the stock is owned by institutional investors.

Boston Scientific Price Performance

BSX opened at $102.71 on Friday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. Boston Scientific Corporation has a 52-week low of $80.64 and a 52-week high of $109.50. The stock has a market capitalization of $152.19 billion, a PE ratio of 61.14, a price-to-earnings-growth ratio of 2.51 and a beta of 0.65. The stock's 50 day moving average price is $104.86 and its 200-day moving average price is $102.26.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm had revenue of $5.06 billion for the quarter, compared to analysts' expectations of $4.89 billion. During the same period in the previous year, the firm earned $0.62 earnings per share. The business's revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, equities research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director Yoshiaki Fujimori sold 2,901 shares of the stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total value of $310,377.99. Following the transaction, the director owned 2,081 shares of the company's stock, valued at approximately $222,646.19. This represents a 58.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company's stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $5,231,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares of the company's stock, valued at approximately $18,659,923.46. The trade was a 21.90% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 174,214 shares of company stock worth $18,397,457 in the last ninety days. Insiders own 0.50% of the company's stock.

Analyst Ratings Changes

BSX has been the subject of a number of recent research reports. Jefferies Financial Group reissued a "hold" rating on shares of Boston Scientific in a research report on Monday, July 21st. Leerink Partnrs upgraded Boston Scientific to a "strong-buy" rating in a report on Monday, June 16th. Citigroup restated a "buy" rating and set a $125.00 price target (up from $119.00) on shares of Boston Scientific in a report on Thursday, May 22nd. Barclays raised their target price on Boston Scientific from $125.00 to $133.00 and gave the company an "overweight" rating in a research report on Thursday, July 24th. Finally, Oppenheimer upgraded Boston Scientific from a "market perform" rating to an "outperform" rating and increased their price target for the stock from $118.00 to $125.00 in a research note on Monday, September 8th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, Boston Scientific has a consensus rating of "Buy" and an average price target of $118.04.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.